Thor Group Limited Overview
THOR is a privately owned, UK-headquartered speciality chemicals group with nearly seven decades of history. It is one of the world's established independent producers of industrial biocides. Its Acticide® franchise preserves water-based paints, coatings, adhesives, polymer emulsions, detergents, fuels and many other products against microbial spoilage.
The group is vertically integrated into its own active substances, such as isothiazolinones, formaldehyde donors, IPBC and quaternary ammonium compounds. Around biocides it has built three adjacent businesses:
-
Disinfection
-
Personal Care, under the Microcare® preservatives brand
-
Performance Chemicals, including Aflammit® flame retardants and the newer Amaval™ multifunctional additives
With €642m of FY2025 turnover, a 19.2% EBITDA margin and €150m of cash, THOR differs from listed peers in three ways. It is debt-free, it pays out most of its earnings as dividends, and it runs a decentralised operating model across 14 operating units. Its main strategic exposures are EU regulation under the BPR and REACH, decorative-coatings demand, and raw-material-driven price competition.
Company's own description. In its FY2025 report, the group describes itself as focused on developing, manufacturing and supplying speciality chemical solutions to a diversified global customer base. It operates through a network of manufacturing sites, distribution sites and technical support centres, supported by central governance, finance, digital, procurement and R&D functions.
The holding company's stated role is to allocate capital, provide governance and leadership, and support strategy execution across its subsidiaries. The group's principal activity is "the manufacture and distribution of speciality chemicals" [TATO-25, Strategic and Directors' Reports].
The group's marketing describes THOR ingredients as everyday but invisible. They preserve washing-up liquids and detergents, protect furniture and clothing in the event of fire, and enhance moisturisers and shampoos [WEB / LinkedIn company profile].
Business model. THOR is a business-to-business ingredients manufacturer. It sells active substances and formulated additives, which customers dose at low concentrations into their own products. FY2025 business units [TATO-25]:
Revenue model. Revenue comes almost entirely from product sales: manufactured goods recognised on despatch. A small "rendering of services" component is associated with product sales [TATO-25, note 1.5]. There are no subscription or licensing revenues of any disclosed significance.
Technical service and microbiological testing are supplied through Technical Service Centres. These centres support sales but are not separately monetised in disclosed figures. Pricing is transactional and competitive. In FY2025 the group reported "continued downwards pressure on market pricing" amid falling raw-material prices, while volumes grew 4.1% [TATO-25].
Value-chain position. THOR sits in the middle of the chemicals value chain. It buys commodity and intermediate raw materials; the largest Scope 3 category is purchased chemicals and raw materials [TATO-25]. It synthesises its own biocidal actives at major sites; the company states isothiazolinones are available from "three major Thor sites" [WEB]. It then formulates finished additive blends.
Customers are formulators such as paint makers, adhesive producers, detergent and cosmetics brands, textile finishers and plastics compounders. Vertical integration into actives is a structural differentiator. In 2025 the group says added capacity reduced its "reliance on third party sourcing for key strategic actives" [TATO-25].
Customer types and end-markets [WEB product pages; TATO-25; CB Insights]:
-
Paints, plasters and decorative coatings. This is the largest single reference market cited in the annual report.
-
Polymer emulsions, adhesives and sealants.
-
Construction and concrete; minerals and slurries.
-
Household products, detergents and wet wipes.
-
Metal-working fluids, fuels, water treatment, and pulp and paper.
-
Plastics and wood-plastic composites (WPC); textiles and leather.
-
Cosmetics, toiletries and personal care.
-
Institutional, industrial and healthcare disinfection, including dialysis-centre applications featured in company news [WEB].
-
Flame-retardant applications in textiles, furniture and plastics.
Independent characterisation. THOR is a mid-sized, family-heritage, regulation-intensive niche player. Its economic moat comes from three things:
-
The cost and duration of maintaining biocide active-substance registrations (EU BPR, UK BPR, US EPA, Mexico COFEPRIS).
-
Captive active-substance manufacturing.
-
Technical-service intimacy with formulators.
Its financial profile is that of a mature, cash-generative industrial business. Revenue has been flat to slightly down since 2022 (FY2022 €688.9m to FY2025 €641.9m). Margins recovered after a 2023 destocking trough, there is no financial debt, and payout ratios run at 80–95% of net profit. Growth is being pursued organically through capacity (the €18m Speyer Building 4) and adjacencies (Personal Care, Disinfection, Performance Chemicals), rather than by acquisition.
Strategy
Stated strategy themes [TATO-25].
The board's six strategic priorities for 2025:
-
Protecting and enhancing gross margins through pricing discipline, manufacturing efficiency and procurement optimisation.
-
Maintaining operational resilience and supply-chain reliability.
-
Disciplined control of fixed costs and headcount growth.
-
Targeted investment in technology, capacity and regulatory capability.
-
Maintaining a strong balance sheet and liquidity.
-
Delivering the 2030 Strategy plan (2025–2030 Strategic Plan, presented to the Main Board in Q1 2025).
The board also describes the business model as "rooted in innovation, quality, and exceptional customer service". It says it continues to review "organic development and selective acquisition opportunities" while staying cautious on the macro outlook. Its forward focus is "capital discipline, portfolio optimisation" and long-term growth, resilience and shareholder value.
Strategic initiatives, last 24 months (Oct 2024 – Oct 2026):
Medium-term financial targets and guidance: not publicly disclosed. No numeric guidance is published. Management states it has produced FY2026 cash-flow forecasts and believes the group is "well positioned to continue to execute its strategy, invest selectively for growth, and meet its obligations" [TATO-25]. Dividend policy is kept under review "in line with its investment plans" [TATO-25].
Products & Services
Pricing models are not publicly disclosed for any product. Products are sold B2B on negotiated or list pricing.
Biocides (Acticide®)
| Product line / application | Description & capabilities | Target customer | Year / status | Source |
|---|---|---|---|---|
| Acticide® (umbrella brand) | International trademark for THOR biocides based on own-manufactured actives: isothiazolinones, formaldehyde donors, IPBC and quats. Protects products in wet/fluid, dry/cured and intermediate states | Formulators across industries | Trademark first registered 1966 | [WEB] |
| Paint & plaster wet-state biocides | In-can preservation of water-based decorative paints and plasters | Paint and coatings manufacturers | Current | [WEB biocides page] |
| Dry-film biocides with AMME | Advanced Micro Matrix Embedding encapsulation protects film-preservative actives, giving controlled release and lower leaching | Façade coatings, plasters, sealants | AMME registered 2011 | [WEB] |
| Polymer emulsion biocides | Preservation of binders and emulsions during manufacture and storage | Emulsion and polymer producers | Current | [WEB] |
| Water treatment / pulp & paper biocides | Slime and microbial control in process water | Paper mills, water treaters | Current | [WEB] |
| Plastics & WPC biocides | Antimicrobial protection for plastics and wood-plastic composites | Compounders | Current | [WEB] |
| Metal-working fluid biocides | Tank-side and in-concentrate preservation | MWF formulators | Current | [WEB] |
| Adhesives & sealants biocides | In-can and dry-film protection | Adhesive manufacturers | Current | [WEB] |
| Textile biocides | Antimicrobial finishing | Textile mills | Current | [WEB] |
| Fuel biocides | Microbial contamination control in fuels | Fuel distributors and users | Current | [WEB] |
| Construction & concrete biocides | Protection of admixtures and construction chemicals | Construction chemicals producers | Current | [WEB] |
| Minerals & slurries biocides | Preservation of mineral slurries (e.g. calcium carbonate, kaolin) | Mineral processors | Current | [WEB] |
| Household & detergent biocides | In-can preservation of detergents and cleaners | Home-care brands | Current | [WEB] |
| Wet-wipe biocides | Preservation of wipe lotions | Wipe manufacturers | Current | [WEB] |
| Leather biocides (Acticide® WB range) | Preservation in beamhouse and tanning processes; historically distributed via a TFL partnership | Tanneries | Partnership date undisclosed | [Leather International] |
| High-purity isothiazolinones | Stabilised high-purity actives with acceptance by US EPA and FDA; supported through the EU BPR | Regulated markets | Current | [WEB legacy biocides page] |
Disinfection
| Product line | Description | Target customer | Source |
|---|---|---|---|
| Quaternary-ammonium-based disinfectants (Acticide® BAC and related) | Quats manufactured by THOR for hard-surface and institutional disinfection. Speyer holds an environmental permit for Acticide BAC production | Institutional cleaning, healthcare and household formulators | [WEB; Speyer permit record] |
| Healthcare / dialysis applications | Company news features THOR solutions supporting dialysis care across 11 centres in Malaysia (date not disclosed) | Healthcare operators | [WEB News] |
Personal Care
| Product line | Description | Target customer | Year | Source |
|---|---|---|---|---|
| Microcare® | Preservatives and antimicrobial ingredients for cosmetics, toiletries and personal care products | Cosmetics and personal care brands | Trademark granted 1999 | [WEB; ipqwery] |
| Emulsifiers / emollients | Listed in THOR trademark specifications for cosmetic chemical products | Cosmetic formulators | Current | [ipqwery] |
Performance Chemicals
| Product line | Description | Target customer | Year | Source |
|---|---|---|---|---|
| Aflammit® | Flame retardants for textiles, furniture and plastics; heritage from the 1972 Dr Quehl acquisition | Textile finishers, plastics compounders | Trademark filed 1998 | [WEB] |
| FR-Plastics business line | Flame retardants dedicated to plastics, run as a global business line | Plastics industry | Current | [theorg.com org chart] |
| Amaval™ multifunctional additives | Multifunctional additives (no further specifications disclosed) | Coatings and formulators | Launched 2024 | [WEB History] |
| Advansil / THOR Silicones | Silicone-based chemicals trademark | Industrial users | Date not disclosed | [ipqwery] |
Services
| Service | Description | Source |
|---|---|---|
| Technical Service Centres | Microbiological testing, application support and regulatory support | [WEB; Prospeo company description] |
| Regulatory support | Dossier support for BPR, REACH, EPA and COFEPRIS registrations | [TATO-23; WEB] |
| Product Carbon Footprint (PCF) data | PCF methodology developed in 2025; data shared with customers through the SiGreen exchange | [TATO-25] |
Financial Narrative
Coverage: Tato Holdings Limited consolidated accounts under UK GAAP (FRS 102), in EUR thousands.
-
FY2022–FY2023 figures: [TATO-23]
-
FY2024–FY2025 figures: [TATO-25]
"Derived" rows are analyst calculations from reported figures. Per-share metrics use about 10.38m shares, inferred because total dividends ÷ DPS equals 10,380k shares in every year.
Income statement
EPS: diluted EPS is not reported (unlisted; no dilutive instruments disclosed).
DPS composition:
Margins and growth
Effective tax rate: FY2022 and FY2023 are the "underlying" rates reported in [TATO-23]. FY2024 and FY2025 are as reported in [TATO-25].
Reported turnover growth: FY2022 is organic growth as reported in [TATO-23]. FY2023 is derived (the company reports −7% organic and −5.2% at constant currency). FY2024 is organic growth per the [TATO-25] KPI table. FY2025 is as reported (+1.1% at constant currency).
Organic volume growth: FY2023 is the KPI figure; the narrative also gives −4.3%.
Revenue CAGR FY2022–FY2025 (derived): −2.3% per year: The decline reflects price normalisation after the 2022 inflation spike and euro translation effects. Volumes over the same period went −4%, +8%, +4.1%, a cumulative increase of roughly 8%.
Commentary.
FY2022 was a price-led peak: Turnover reached €688.9m with 14% organic growth despite a 7% volume decline. Selling-price inflation more than offset lost tonnage, and EBITDA margin hit 20.4%.
FY2023 was the trough: Customers destocked and raw-material deflation passed through to selling prices. Turnover fell to €642.4m, gross margin compressed to 29.4% and EBITDA margin fell to 16.4%. Operating profit fell 31.5% to €83.2m.
FY2024 brought a volume-led recovery: Volumes rose 8%. Operating profit rose to €99.9m even after two one-offs:
-
€13.3m of South Africa historical clean-up costs
-
€1.6m of Turkish hyperinflation effects
FY2025 showed underlying margin resilience: Reported turnover was down 1.1% because of the weaker US dollar, but constant-currency turnover was up 1.1%. Gross margin improved to 37.0% from pricing discipline, lower material costs, mix and better capacity utilisation. Operating profit slipped 1.5%. Reported overheads rose only 1.2%, but the FY2024 base included the one-offs; excluding them, overheads rose 16.5%. Drivers of that increase:
-
Unrealised FX losses in Mexico
-
Wage inflation and investment in people
-
Higher depreciation
-
Impairments in Mexico and France
-
A new slow-moving stock provisioning policy
The lower effective tax rate (27.2%) lifted net profit 8.9% to €76.9m [TATO-25].
Balance sheet
Total assets (derived): fixed assets plus current assets.
Goodwill: none is shown on the face of the balance sheet. Intangibles are acquired software and capitalised third-party product registration costs [TATO-25 note 1.8].
Debt. No bank borrowings are presented on the face of the balance sheets reviewed. Interest payable was only €120k in FY2024 and €170k in FY2025, consistent with negligible debt. The group says it uses overdrafts and short-term loans "when required" [TATO-25].
-
Total debt (short/long split): not separately disclosed; immaterial.
-
Net debt: negative, i.e. a net cash position of about €149.6m at FY2025 (€170.1m at FY2024).
-
The content of "creditors due after more than one year" (€4.6m) was not itemised in the extract.
Cash flow
-
Net cash from operating activities is after tax and interest received.
-
FY2025 capex was €28.6m tangible plus €4.0m intangible; the company reports €32.6m invested in fixed assets.
-
No share buybacks are disclosed.
Commentary. Cash flow is dominated by working capital:
FY2022: operating cash conversion was weak (€46.0m) because the group built inventory to €219.9m, or 210 stock days, during supply-chain disruption.
FY2023: destocking released about €63m of inventory. Operating cash flow reached €140.3m, a 138% cash conversion ratio per [TATO-23], and cash rose to €156.9m.
FY2024–FY2025: inventories were deliberately rebuilt to support service levels, rising to €164.2m (143 days).
FY2025 tax: tax paid rose 50% to €34.5m. Together with the higher dividend of €72.7m and capex of €32.6m, this produced the first net cash outflow in the period, €18.6m before FX. The company says it "expended €20,413,000 cash in 2025".
Ratios
ROIC: is approximated with no debt, using NOPAT = operating profit × (1 − effective tax rate).
Debt to equity: is about zero, since no borrowings were identified.
Net debt to EBITDA: is negative because the group holds net cash.
Cash conversion cycle: creditor days are not disclosed, so the full cycle cannot be computed. Stock days plus debtor days were:
Commentary. Returns are moderate (ROE 10–15%) rather than high, held down by a very large, under-levered equity base. Equity is €639m against €150m of cash and only €61m of short-term creditors. On a cash-adjusted basis (ROIC about 14–17%), the operating business earns attractive returns.
The working-capital intensity, at more than 200 days of stock plus debtors, is structurally high. The board treats it as a deliberate service strategy: holding "high levels of strategic inventories" to protect customers against supply disruption [TATO-25]. Debtor days have crept up from 57 to 72 over three years, which merits monitoring.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Business Units
| Business unit (as named in FY2025 report) | Contents (from company product pages) | FY2025 directional performance [TATO-25] |
|---|---|---|
Biocides (Industrial Biocides) | Acticide® in-can, wet-state and dry-film preservatives; isothiazolinones (MIT, BIT, CMIT/MIT, OIT/DCOIT families), formaldehyde donors, IPBC, AMME-encapsulated dry-film biocides; applications in paints, plasters, emulsions, adhesives, fuels, MWF, water treatment, pulp and paper, plastics/WPC, textiles, leather, construction, slurries, household and wet wipes | Broadly flat, with regional variations |
Disinfection | Quaternary ammonium compound (quat) based disinfectant actives and formulations, e.g. the Acticide® BAC range permitted at Speyer; healthcare and institutional applications | Grew year on year |
Personal Care | Microcare® preservatives and ingredients for cosmetics, toiletries and personal care; emulsifiers and emollients (per trademark specifications) | Grew year on year |
Performance Chemicals | Aflammit® flame retardants (textiles, plastics; the "FR-Plastics" business line appears in org-chart data); Amaval™ multifunctional additives (2024); Advansil silicones trademark | Grew year on year |
Revenue by Segment
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Group turnover (EUR K) | 688,906 | 642,380 | 648,974 | 641,878 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Turnover (EUR K) | 688,906 | 642,380 | 648,974 | 641,878 |
Gross profit (EUR K) | 226,468 | 188,808 | 237,415 | 237,365 |
Operating profit (EUR K) | 121,423 | 83,179 | 99,929 | 98,440 |
Depreciation and impairment of tangibles (EUR K) | 17,892 | 21,079 | 21,118 | 23,140 |
Amortisation of intangibles (EUR K) | 1,284 | 1,415 | 1,586 | 1,838 |
EBITDA, derived as operating profit plus D&A (EUR K) | 140,599 | 105,673 | 122,633 | 123,418 |
Profit before tax (EUR K) | 123,452 | 88,220 | 106,812 | 105,616 |
Tax charge (EUR K) | 30,617 | 23,362 | 36,197 | 28,712 |
Profit after tax (EUR K) | 92,835 | 64,858 | 70,615 | 76,904 |
EPS basic, derived (EUR) | 8.94 | 6.25 | 6.80 | 7.41 |
Dividends per share declared and paid (EUR) | 6.00 | 5.00 | 5.50 | 7.00 |
Dividend History
| Fiscal year | Payments | Total DPS |
|---|---|---|
FY2022 | €3 in March + €3 in December | €6.00 |
FY2023 | €2 in April + €3 in October | €5.00 |
FY2024 | €2 in April + €3.50 in October | €5.50 |
FY2025 | €3 in April + €4 in October | €7.00 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Gross margin, as reported (%) | 32.9 | 29.4 | 36.6 | 37.0 |
EBITDA margin, company-reported (%) | 20.4 | 16.4 | 18.9 | 19.2 |
Operating margin, derived (%) | 17.6 | 12.9 | 15.4 | 15.3 |
Pre-tax margin, derived (%) | 17.9 | 13.7 | 16.5 | 16.5 |
Net margin, derived (%) | 13.5 | 10.1 | 10.9 | 12.0 |
Effective tax rate (%) | 24.8 | 26.5 | 33.9 | 27.2 |
Reported turnover growth (%) | 14.0 | -6.8 | 1.0 | -1.1 |
Organic volume growth (%) | -7.0 | -4.0 | 8.0 | 4.1 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Intangible assets (EUR K) | 3,384 | 3,453 | 3,887 | 5,975 |
Tangible assets (EUR K) | 280,483 | 283,138 | 283,124 | 281,690 |
Stocks (EUR K) | 219,897 | 157,011 | 162,407 | 164,154 |
Trade and other debtors (EUR K) | 125,771 | 125,059 | 120,210 | 126,487 |
Cash and cash equivalents (EUR K) | 89,620 | 156,933 | 170,076 | 149,620 |
Total assets, derived (EUR K) | 719,155 | 725,594 | 739,704 | 727,926 |
Creditors due within one year (EUR K) | 63,422 | 56,191 | 59,978 | 61,256 |
Creditors due after one year (EUR K) | 2,103 | 4,000 | 4,190 | 4,557 |
Provisions for liabilities (EUR K) | 23,200 | 17,786 | 25,314 | 23,199 |
Net current assets (EUR K) | 371,866 | 382,812 | 392,715 | 379,005 |
Shareholders' funds (EUR K) | 630,430 | 647,617 | 650,222 | 638,914 |
Goodwill (EUR K) | 0 | 0 | 0 | 0 |
Cash Flow and Returns & Leverage Ratios (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Operating cash flow before working capital (EUR K) | 133,346 | 102,621 | 126,747 | 122,482 |
Net cash from operating activities (EUR K) | 45,959 | 140,274 | 97,240 | 86,579 |
Capital expenditure, tangible plus intangible (EUR K) | 29,525 | 21,901 | 26,056 | 32,592 |
Free cash flow, derived as OCF minus capex (EUR K) | 16,434 | 118,373 | 71,184 | 53,987 |
Dividends paid (EUR K) | 62,280 | 51,900 | 57,090 | 72,660 |
Share buybacks (EUR K) | 0 | 0 | 0 | 0 |
Tax paid (EUR K) | — | — | 23,029 | 34,453 |
Dividend payout ratio, derived (%) | 67.1 | 80.0 | 80.8 | 94.5 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio (derived) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
ROE on closing equity (%) | 14.7 | 10.0 | 10.9 | 12.0 |
ROA on closing total assets (%) | 12.9 | 8.9 | 9.5 | 10.6 |
ROIC, NOPAT over (equity minus cash) (%) | 16.9 | 12.5 | 13.8 | 14.6 |
Current ratio (x) | 6.86 | 7.81 | 7.55 | 7.19 |
Debt to equity (x) | 0 | 0 | 0 | 0 |
Net debt to EBITDA (x) | -0.64 | -1.49 | -1.39 | -1.21 |
Interest coverage, operating profit over interest payable (x) | — | — | 833 | 579 |
Asset turnover (x) | 0.96 | 0.89 | 0.88 | 0.88 |
Average stock days, company KPI | 210 | 145 | 136 | 143 |
Average trade debtor days, company KPI | 57 | 60 | 68 | 72 |
Working Capital (Days)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Stock days plus debtor days | 267 | 205 | 204 | 215 |
Revenue by Region
| Region | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Group turnover (EUR K) | 642,380 | 648,974 | 641,878 |
Region Overview
| Region | FY2025 commentary | Assessment |
|---|---|---|
APAC | Strongest volume growth, driven primarily by new business wins | Fastest-growing region by volume. Supported by the China (Zhenjiang) manufacturing hub, India subsidiary (2023), new South Korea branch (2025) and Malaysia plant renovation |
Americas | Strong first half; demand softened in H2 2025; USD translation was a material headwind; Mexico had FX losses and impairments | Volume positive but reported-euro contribution weakened. US tariffs prompted the group to rebalance production across its global footprint |
EMEA | Contributed volume growth, but conditions stayed challenging, with pressure in construction-related markets and persistent price competition, partly offset by mix | The weakest region on pricing. Decorative coatings volumes −0.2% and revenues −0.9% globally in 2025 |
Capital Markets
| Item | Status |
|---|---|
Share price performance (1/3/5-year) | Not applicable: unlisted; no traded price |
Valuation multiples (P/E, EV/EBITDA, EV/Sales, P/B) | Not applicable / not publicly disclosed |
Book-value reference | Shareholders' funds €638.9m at FY2025, about €61.55 per share (derived, about 10.38m shares) |
Analyst consensus | None; no sell-side coverage |
Credit ratings (Moody's / S&P / Fitch) | None; no rated debt |
Debt maturity profile | Not applicable: no bank borrowings identified; creditors due after one year €4.6m (composition not itemised) |
Buyback authorisations | None disclosed. A capital redemption reserve of €250k indicates a historical share repurchase or redemption |
Dividend policy | No formal policy published. Interim dividends paid twice a year; the board reviews dividends "in line with its investment plans and business objectives" [TATO-25] |
Per-Share Data and Dividends & Capital Returns
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Dividend per share (EUR) | 6.00 | 5.00 | 5.50 | 7.00 |
Total dividends paid (EUR K) | 62,280 | 51,900 | 57,090 | 72,660 |
Payout ratio of profit after tax (%) | 67.1 | 80.0 | 80.8 | 94.5 |
Dividend as share of opening cash (%) | — | 69.5 | 36.4 | 42.7 |
Analyst Conclusions
Management guidance. No quantitative guidance is published. Management says:
-
The group is well positioned to execute strategy and "invest selectively for growth".
-
FY2026 cash-flow forecasts support going concern.
-
The focus is on capital discipline, portfolio optimisation, and selective organic and inorganic opportunities [TATO-25].
Consensus expectations: none (no analyst coverage).
Bull case:
-
Operating leverage from volume. Volumes have grown in consecutive years (+8% in FY2024, +4.1% in FY2025) while gross margin expanded to 37.0%. Once pricing stabilises as raw-material deflation runs its course, the 40,000 t Speyer expansion could translate volume into reported revenue growth and margin above 20% EBITDA.
-
Balance-sheet optionality. €149.6m of net cash and no debt allow the group to keep its €70m-plus annual dividend, fund capex of about €30m, and pursue selective acquisitions at once. As one of the last scaled independent biocide makers, it could also attract strategic interest.
-
Adjacency mix shift. Disinfection, Personal Care and Performance Chemicals all grew in FY2025, APAC delivered the strongest growth, and Amaval is a new platform. Together these diversify the group away from cyclical EMEA decorative coatings.
Bear case:
-
Structural price deflation. Turnover is 6.8% below FY2022 despite higher volumes. Asian competition and raw-material pass-through may keep eroding average selling prices.
-
Regulatory concentration. A large share of the portfolio rests on isothiazolinones and formaldehyde donors under tightening EU CLP, BPR and REACH regimes. A reclassification or non-renewal could strand capacity.
-
Cost and capital drag. Underlying overheads rose 16.5% in FY2025, debtor days rose to 72, and stock days are 143. A 94.5% payout leaves a thin buffer: cash already fell €20m in FY2025 even before any 2026 shocks from the Middle East conflict, energy costs or FX.
Catalysts and monitorables (next 12 months):
-
FY2026 accounts (expected around May 2027): whether Speyer volumes lift turnover above €650m, and whether the EBITDA margin holds at or above 19%.
-
Q3 2026 decision on a science-based target, and the climate KPIs to follow.
-
Any acquisition announcement drawing on the cash pile.
-
USD/EUR movements and tariff developments affecting the Americas.
-
Energy and logistics effects of the Middle East conflict.
-
EU regulatory decisions on isothiazolinone and quat active-substance renewals.
-
Trends in debtor days and stock days.
-
Changes in dividend cadence.
-
Filing of Thor Group Limited's FY2025 small-company accounts (due 30 September 2026).
Analyst verdict. THOR, operating legally through Thor Group Limited and consolidated under Tato Holdings Limited, is a disciplined, conservatively financed, family-heritage speciality chemicals business. On cash returns and resilience it compares well with many listed peers. On top-line momentum and transparency it compares poorly.
The FY2025 accounts show the group's core competence: holding gross margin at 37% and EBITDA margin at 19.2% in a year when its largest end-market, decorative coatings, contracted and selling prices fell. Captive active-substance production and a decentralised, service-intensive model underpin that resilience, and the €18m Speyer expansion signals confidence in volume growth.
The weaknesses are equally clear. Reported revenue has drifted down for three years, to a 2.3% compound decline since the FY2022 inflation peak. Overheads are growing faster than gross profit, and working capital consumes more than 200 days of sales in stock and receivables. The capital-allocation stance has become notably shareholder-friendly. The FY2025 payout of 94.5% of earnings, combined with higher tax payments and capex, produced the first year of net cash outflow in the period. That is sustainable from a €150m cash pile, but not indefinitely unless earnings grow.
For counterparties, THOR is a low-credit-risk, financially robust supplier. Its exposure lies in regulation and pricing, not solvency. For potential acquirers or investors, its scale (about €640m revenue), regulatory estate and independence make it one of the few remaining mid-sized biocide assets globally.
The main monitorables:
-
Whether Speyer and APAC growth convert volume gains into revenue growth.
-
Whether management delivers on its newly formalised climate targets.
-
Whether the "selective acquisition" language becomes action.
Overall assessment: financially strong, strategically steady, growth-constrained. Its outlook is stable, with balance-sheet-driven upside optionality.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Nationality | Role (from website / report) | Tenure / background | Source |
|---|---|---|---|---|
David A. Hewitt | British | Group CEO; director | Nearly 40 years at THOR; on the Executive Board for almost 30 years; Group CEO since 2020; oversaw construction of the Wincham site (2001). Also a director of Thor Group Limited | [WEB Exec Board; TATO-25; CH] |
P. J. (Philip) McDonald | British | Group CFO | Joined 2022 from senior finance roles at NSG Pilkington and the Hempel Group. Responsible for Finance, Procurement and Digital; member of the Audit & Risk, Ethics and Budget committees | [WEB; TATO-25] |
P. (Peter) Hahn | German | Chief Sales Officer | Board member since 2007 (industrial biocides); CSO since 2019 with global commercial responsibility | [WEB; TATO-25] |
Q. (Qinglin) Zheng | Chinese | Executive director, APAC | Joined THOR China in 2016; PhD in Chemistry; based in Zhenjiang; responsible for China, Malaysia, Australia and Japan | [WEB; TATO-25] |
R. Baum | German | Executive director | Exec Board page refers to a member who completed a chemical engineering degree in the 1990s and became Head of R&D for biocides at THOR Germany. Attribution to R. | [WEB; TATO-25] |
G. De Lucia | Italian | Executive director | — | [TATO-25] |
D. Siroky | American | Executive director | — | [TATO-25] |
I. Lobley | British | Non-Executive Director | Shareholder representative | [TATO-25] |
A. (Albert) Sanders-Champney | British | Non-Executive Director | Appointed 30 Jun 2023, replacing Kevin Howes; shareholder representative | [TATO-23; TATO-25] |
S. (Simon) Pearson | British | Company Secretary | Also director and secretary of Thor Group Limited | [TATO-25; CH] |
Governance Overview
| Feature | Detail |
|---|---|
Board size | 9: 7 executive and 2 non-executive directors |
Independence | The two NEDs represent the primary shareholders, so neither is independent in the listed-company sense. No independent directors are disclosed |
Chair / CEO separation | The identity of the chair is not disclosed |
Committees | Audit & Risk (met twice in 2025); Ethics & Compliance; Remuneration & Nomination; Sustainability (formed early 2026, first meeting May 2026) |
Other bodies | Executive Board (7 members from Europe, China and the USA); Budget Committee |
Board agenda conventions | Health & Safety is the first substantive item at every Board meeting. ESG is a standing item twice a year. Cyber is a rolling item at every Main Board meeting |
Board & Management Changes
| Date | Change |
|---|---|
| 2020 | David Hewitt becomes Group CEO |
| 2022 | Philip McDonald joins as Group CFO |
30 Jun 2023 | Kevin Howes (NED) resigns; Albert Sanders-Champney appointed |
| 2023 | New Heads of Digital, Audit & Risk, and Financial Planning & Analysis appointed |
Apr 2024 | Head of Group Audit & Risk Management and Group Digital Communications & Content Manager join |
Q1 2026 | Group Head of Sustainability recruited |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Ownership | Relative positioning vs. THOR |
|---|---|---|---|
Industrial biocides | LANXESS (Material Protection Products, incl. ex-IFF/Dow Microbial Control acquired 2022) | Listed (Germany) | Largest global biocides portfolio after the acquisition; broader actives slate. THOR is smaller but independent and focused |
Industrial biocides | Arxada (ex-Lonza Specialty Ingredients, incl. Troy Corp, acquired 2022) | Private-equity owned | Strong in dry-film and wood/material protection, where it overlaps with THOR's AMME dry-film range |
Industrial biocides | Vink Chemicals | Private (Germany) | Mid-sized biocide specialist; direct competitor in coatings preservation |
Industrial biocides | Chinese isothiazolinone producers (various) | Private / listed China | Price competition in commodity isothiazolinones, a source of FY2025 pricing pressure |
Disinfection | Lonza / Arxada, LANXESS, Stepan, Ecolab (formulated disinfectants) | Mixed | Quat actives and formulated disinfection; THOR is a niche quats producer |
Personal care preservatives | Ashland, Symrise, Schülke & Mayr, LANXESS, Clariant | Listed / private | Larger cosmetic-ingredient portfolios; THOR's Microcare is a niche preservative play |
Flame retardants | ICL, Clariant (Exolit), Albemarle, LANXESS | Listed | Much larger FR producers; THOR's Aflammit is focused on textiles and plastics niches |
Industrial biocides / cleaning (UK niche) | Chela, Oxi-Tech Solutions, Anolytech, Goldshield (per CB Insights) | Private | Small UK disinfection players; marginal overlap |
Distribution-led competitors | IMCD, Brenntag (as channels for rival actives) | Listed | Distribute competitors' products; also potential partners |
Competitor Detail
| Metric | THOR (FY2025) |
|---|---|
Revenue (EUR Mn) | 641.9 |
Revenue growth (%) | -1.1 |
EBITDA margin (%) | 19.2 |
Net cash (EUR Mn) | 149.6 |
Recent Developments
THOR is private and publishes limited news, so several entries come from the FY2025 annual report and are dated at quarter or year level.



